US 12,077,784 B2
Suspension system for adeno associated virus production
Xin Yu, Zhangiagang (CN); Xavier de Mollerat du Jeu, Encinitas, CA (US); Chao Yan Lin, Germantown, MD (US); Jian Liu, Carlsbad, CA (US); and Jonathan Zmuda, Frederick, MD (US)
Assigned to Life Technologies Corporation, Carlsbad, CA (US)
Filed by Life Technologies Corporation, Carlsbad, CA (US)
Filed on Feb. 13, 2023, as Appl. No. 18/168,396.
Application 18/168,396 is a division of application No. 16/798,193, filed on Feb. 21, 2020, granted, now 11,608,491.
Claims priority of provisional application 62/809,407, filed on Feb. 22, 2019.
Prior Publication US 2023/0193214 A1, Jun. 22, 2023
Int. Cl. C12N 1/06 (2006.01); C12N 1/22 (2006.01); C12N 7/00 (2006.01); C12N 15/10 (2006.01); C12N 15/86 (2006.01)
CPC C12N 7/00 (2013.01) [C12N 1/06 (2013.01); C12N 15/86 (2013.01); C12N 2750/14041 (2013.01); C12N 2750/14152 (2013.01)] 20 Claims
 
1. An adeno-associated virus (AAV) production system, comprising:
(a) mammalian cells adapted for suspension culture;
(b) an AAV transfer vector;
(c) one or more packaging plasmids;
(d) an enhancer comprising one or more histone deacetylase (HDAC) inhibitor; and
(e) cell culture media that supports growth and expansion of the mammalian cells.